KPBS examines microbicide research as M2010 concludes

KPBS reports on researchers' efforts to develop novel methods to protect women from HIV infection that have been examined at the International Microbicides Conference (M2010) in Pittsburgh this week. In sub-Saharan Africa, one of the region's hardest hit by HIV/AIDS, "six out of ten adults living with the virus are women," KPBS writes. The piece names several factors that increase women's vulnerability to HIV transmission in the region and the need "for protection [against HIV] that women can use discreetly," such as microbicides.

The article details several promising microbicides in development, such as vaginal rings, films and tablets, and includes comments by Ian McGowan, co-principal investigator of the Microbicides Trial Network, and Joseph Romano, the chief of product development for the International Partnership for Microbicides (Goldberg, 5/25).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients